Cell Banking, Cryopreservation & Autologous Regenerative Medicine
Ep. 85 - Drew Taylor
43 minute view/listen
Autologous cell treatments are already making an impact in our lives today but the truth is we are only just scratching the surface of what might be possible.
In our lifetime, aesthetic regenerative medicine will make a dramatic leap forward. The problem is that as our cells age they become less potent. That means many of us will never be able to experience the full impact of emerging regenerative innovation.
On episode no. 85 of the Technology of Beauty we hear from the CEO of a startup that has not only set out to solve this problem, but already has a solution in the marketplace designed to prepare today's generation for the regenerative advances ahead.
Meet Acorn Biolabs — The first non-invasive solution to preserve your younger follicle cells for use in regenerative medicine.
From locking in cell age with cryogenic preservation to developing a process for autologous cell regeneration that could speculatively allow for 3D-printing a pancreas, Acorn CEO Drew Taylor describes it all so clearly that it feels less like science fiction, and more like inevitable future fact.
But if it still seems too far off, or too good to be true, the first applications for these autologous cell-based therapies lie squarely in the realm of aesthetic medicine, where they are currently testing applications for their first cell-derived product composed of iPSCs — induced pluripotent stem cells.
Find out what it all means and stick around for a demonstration of the harvesting procedure on Dr. Grant Stevens himself on the latest episode of The Technology of Beauty.
The Technology of Beauty
Produced and co-founded by Influx, The Technology of Beauty is the podcast of renowned plastic surgeon Dr. Grant Stevens. Tune in to hear interviews with the innovators and entrepreneurs and who are shaping the future of aesthetics from the industry side.